Accelerate Diagnostics Completes $45M Rights Offering | GenomeWeb

NEW YORK (GenomeWeb News) – Accelerate Diagnostics said today it raised $45 million from a rights offering commenced last month.

About $25.5 million was raised from shareholders who subscribed for more than 1.5 million shares of the Tucson, Ariz.-based firm's common stock. It said that approximately 58 percent of the shares were subscribed for by Accelerate's directors, and added that 57 percent of stockholders exercised their subscription privileges.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.